HR 5723
115th Congress
House
Health
Congressional oversight
Drug trafficking and controlled substances
Drug, alcohol, tobacco use
Health information and medical records
Home and outpatient care
Hospital care
Medicare
Prescription drugs
Expanding Oversight of Opioid Prescribing and Payment Act of 2018
Everywhere this bill has been
15 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jun 20, 2018
Received in the Senate and Read twice and referred to the Committee on Finance.
Jun 19, 2018
Motion to reconsider laid on the table Agreed to without objection.
Jun 19, 2018
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5264)
Jun 19, 2018
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.(text: CR H5264)
Jun 19, 2018
DEBATE - The House proceeded with forty minutes of debate on H.R. 5723.
Jun 19, 2018
Considered under suspension of the rules. (consideration: CR H5264-5265)
Jun 19, 2018
Mr. Roskam moved to suspend the rules and pass the bill, as amended.
Jun 19, 2018
Placed on the Union Calendar, Calendar No. 592.
Jun 19, 2018
Committee on Energy and Commerce discharged.
Jun 19, 2018
Reported (Amended) by the Committee on Ways and Means. H. Rept. 115-760, Part I.
May 22, 2018
Referred to the Subcommittee on Health.
May 16, 2018
Ordered to be Reported (Amended) by Voice Vote.
May 16, 2018
Committee Consideration and Mark-up Session Held.
May 9, 2018
Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
May 9, 2018
Introduced in House
Plain-English summary
Expanding Oversight of Opioid Prescribing and Payment Act of 2018
(Sec. 2) This bill requires the Medicare Payment Advisory Commission to report to Congress on: (1) how Medicare pays for opioid and non-opioid pain management treatments in inpatient and outpatient hospital settings; (2) current incentives for prescribing opioid and non-opioid treatments under Medicare inpatient and outpatient prospective payment systems, along with recommendations to address any identified adverse incentives; and (3) how opioid use is currently tracked and monitored through Medicare and any areas for improvement.
What's happening now
Received in the Senate and Read twice and referred to the Committee on Finance.
Committees of jurisdiction
4
Cosponsors
1